Prognostic factors in endometrial carcinoma

Annals of the Academy of Medicine Singapore

Volumn 28, Issue 2, 1999, Pages 266-271

  Chew, S H ^a  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

Clear cell carcinoma; Lympho vascular space involvement; Peritoneal cytology; Ploidy; Uterine serous carcinoma

Indexed keywords

ADENOCARCINOMA; AGE; CANCER INVASION; CANCER STAGING; CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SINGAPORE; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; AGE FACTORS; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SINGAPORE; SURVIVAL RATE;

EID: 0033094197     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Chia K S, Lee H P, Seow A, Shanmugaratnam K. Trends in cancer incidence in Singapore 1968-1992. Report No. 4. Singapore: Singapore Cancer Registry, 1996:21,23,25,102.
2. Beckner M E, Mori T, Silverberg S G. Endometrial carcinoma: nontumor factors in prognosis. Int J Gynecol Pathol 1985; 4:131-45
3. Steinhorn S C, Myers M H, Hankey B F, Pelham V F. Factors associated with survival differences between black women and white women with cancer of the uterine corpus. Am J Epidemiol 1986; 124:85-93.
4. Abeler V M, Kjorstad K E. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991; 67:3093-103.
5. Bokhman J V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10-7.
6. Nyholm H C, Nielsen A L, Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics. Gynecol Oncol 1993; 49:229-35.
7. Zaino R J, Kurman R J, Diana K L, Morrow C P. Pathologic models to predict outcome for women with endometrial adenocarcinoma - the importance of the distinction between surgical stage and clinical stage. A Gynecologic Oncology Group study. Cancer 1996; 77:1115-21.
8. Kaku T, Tsuruchi N, Tsukamoto N, Hirakawa T, Kamura T, Nakano H. Reassessment of myometrial invasion in endometrial carcinoma. Obstet Gynecol 1994; 84:979-82
9. Templeton A C. Reporting of myometrial invasion by endometrial carcinoma. Histopathology 1982; 6:733-7.
10. Boente M P, Yordan E L Jr, McIntosh D G, Grendys E C Jr, Orandi Y A, Davies S, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 1993; 51:316-22.
11. Creasman W T, Morrow C P, Bundy B N, Homesley H D, Graham J E, Heller P B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60:2035-41.
12. Schink J C, Rademaker A W, Miller D S, Lurain J R. Tumor size in endometrial cancer. Cancer 1991; 67:2791-4.
13. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6:93-108.
14. Carcangiu M L, Chambers J T. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol Oncol 1992; 47:298-305.
15. Silva E G, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990; 3:120-8.
16. Sherman M E, Bitterman P, Rosenshein N B, Delgado G, Kurman R J. Uterine serous carcinoma - a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16:600-10.
17. Clement P B, Scully R E. Endometrial hyperplasia and carcinoma. In: Clement P B, Young R H, editors. Tumors and Tumor-like Lesions of the Uterine Corpus and Cervix. USA: Churchill Livingstone, 1993:181-264.
18. Abeler V M, Vergote I B, Kjorstad K E, Trope C G. Clear cell carcinoma of the endometrium-Prognosis and metastatic pattern. Cancer 1996; 78:1740-7.
19. Malpica A, Tornos C, Burke T W, Silva E G. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 1995; 19:769-74.
20. Connelly P J, Alberhasky R C, Christopherson W M. Carcinoma of the endometrium: III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 1982; 59:569-75.
21. Genest P, Drouin P, Gerig L, Girard A, Stewart D, Prefontaine M. Prognostic factors in early carcinoma of the endometrium. Am J Clin Oncol 1987; 10:71-7.
22. Lurain J R, Rice B L, Rademaker A W. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1991; 78:63-9.
23. Gal D, Recio F O, Zamurovic D, Tancer M L. Lymphovascular space involvement - a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol 1991; 42:142-5.
24. Ambros R A, Kurman R J. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 1992; 69:1424-31.
25. Turner D A, Gershenson D M, Atkinson N, Sneige N, Taylor W. The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 1989; 74:775-80.
26. Lurain J R, Rumsey N K, Schink J C, Wallemark C B, Chmeil J S. Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1989; 74:175-9.
27. Kadar N, Homesley H D, Malfetano J H. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992; 46:145-9.
28. Lurain J R. The significance of positive peritoneal cytology in endometrial cancer [editorial]. Gynecol Oncol 1992; 46:143-4.
29. Ulbright T M, Roth L M. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 1985; 16:28-34.
30. Eifel P, Hendrickson M, Ross J, Ballon S, Martinez A, Kempson R. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer 1982; 50:163-70.
31. Pertschuk L P, Masood S, Simone J, Feldman J G, Fruchter R G, Axiotis C A, et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 1996; 63:28-33.
32. Kadar N, Malfetano J H, Homesley H D. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 1993; 50:281-6.
33. Vecek N, Nola M, Marusic M, Ilic J, Babic D, Petrovecki M, et al. Prognostic value of steroid hormone receptors concentration in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1994; 73:730-3.
34. Ehrlich C E, Young P C M, Stehman F B, Sutton G P, Alford W M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988; 158:796-807.
35. Sherman M E, Bur M E, Kurman R J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26:1268-74.
36. Zheng W, Cao P, Zheng M, Kramer E E, Godwin T A. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes [see comments]. Gynecol Oncol 1996; 61:167-74.
37. Geisler J P, Wiemann M C, Zhou Z, Miller G A, Geisler H E. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996; 61:245-8.
38. Pisani A L, Barbuto D A, Chen D, Ramos L, Lagasse L D, Karlan B Y. HER-2/neu, p53 and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995; 85:729-34.
39. Reinartz J J, George E, Lindgren B R, Niehans G A. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and cerbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994; 25:1075-83.
40. Nordstrom B, Strang P, Lindgren A, Bergstrom R, Tribukait B. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int J Gynecol Pathol 1996; 15:191-201.
41. Britton L C, Wilson T O, Gaffey T A, Cha S S, Wieand H S, Podratz K C. DNA ploidy in endometrial carcinoma: major objective prognostic factor. Mayo Clin Proc 1990; 65:643-50.
42. Susini T, Rapi S, Savino L, Boddi V, Berti P, Massi G. Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical-pathologic parameters. Am J Obstet Gynecol 1994; 170:527-34.
43. Friberg L G, Noren K N, Delle U. Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II: a prospective 5-year survival study. Gynecol Oncol 1994; 53:54-9.
44. Iversen O E, Utaaker E, Skaarland E. DNA ploidy and steroid receptors as predictors of disease course I patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1988; 67:531-7.
45. Xue F, Jiao S, Zhao F. A study on DNA content and cell cycle phase analysis in endometrial carcinoma. Chung Hua Fu Chan Ko Tsa Chih 1996; 31:216-9.
46. Hetzel D J, Wilson T O, Keeney G L, Roche P C, Cha S S, Podratz K C. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992; 47:179-85.
47. Nazeer T, Ballouk F, Malfetano J H, Figge H, Ambros R A. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. Am J Obstet Gynecol 1995; 173:1829-34.
48. Saffari B, Jones L A, El-Naggar A, Felix J C, George J, Press M F. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival. Cancer Res 1995; 55:5693-8.